Pillar Biosciences and Hamilton Partner to Automate NGS Testing with Advanced Liquid Handling Systems
核心洞察
Pillar Biosciences (搜索) and Hamilton Company (搜索) have formed a strategic partnership to develop automated NGS testing solutions, initially focusing on the oncoReveal (搜索) Essential MPN (搜索) panel.
The collaboration aims to address key barriers in NGS testing adoption by combining Pillar's NGS products with Hamilton's Microlab STAR Liquid Handling Systems to reduce time, costs, and workflow complexity.
The partnership will cover markets across North America, Central America, South America, New Zealand, and APAC Countries, expanding access to efficient NGS testing solutions.
In a significant move to advance precision medicine capabilities, Pillar Biosciences (搜索), Inc., a leader in Decision Medicine™, has established a strategic partnership with Hamilton Company (搜索) to automate next-generation sequencing (NGS) testing processes. The collaboration, announced today, focuses on developing automation scripts and technical solutions for Pillar's research-use-only (RUO) NGS panels.
The partnership's initial phase will center on automating Pillar's oncoReveal (搜索)® Essential MPN (搜索) panel using Hamilton's sophisticated Microlab® STAR™ Liquid Handling Systems. This integration aims to streamline complex NGS testing workflows and enhance laboratory efficiency.
Addressing Market Challenges
"Time, workflow complexity and overall testing costs are barriers for the broader adoption of localized NGS testing solutions," explained Dan Harma, CCO of Pillar Biosciences (搜索). The collaboration seeks to overcome these obstacles by combining Pillar's streamlined NGS products with Hamilton's automated liquid handling expertise.
The partnership promises to deliver several key benefits to laboratories and healthcare providers:
- Faster turnaround times for tumor profiling results
- Reduced labor costs through automation
- Enhanced testing efficiency and reliability
- Broader access to NGS testing capabilities
Technology Integration and Market Impact
Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton, emphasized the strategic value of the partnership: "By combining Pillar's cutting-edge NGS solutions with Hamilton's proven automation technology and global reach, we are providing customers with a more accessible and efficient solution to accelerate NGS testing."
The automation solutions will leverage Pillar's proprietary technologies, including SLIMamp (搜索)® and PiVAT (搜索)®, which are designed to localize testing processes and reduce diagnostic costs. This integration with Hamilton's automated systems aims to create a more streamlined and accessible NGS testing ecosystem.
Geographic Expansion
The application development and co-marketing agreement encompasses a broad geographic scope, including:
- North America
- Central America
- South America
- New Zealand
- All APAC Countries
This extensive coverage ensures that laboratories across these regions will have access to advanced NGS automation solutions, potentially transforming how genetic testing is conducted in these markets.